Table 2 Descriptive statistics of the respondents’ demographic characteristics presented as percentages, mean, or median with statistical testing between the different perceptions of whether the embryo is more than a lump of cells or only a lump of cells

P value

(ANOVA^a)

Age (years)

 Mean (SD)

67.7 (8.86)

65.9 (8.96)

66.7 (8.95)

0.31

 Median [Min, Max]

70.0 [40.0, 84.0]

67.5 [30.0, 84.0]

69.0 [30.0, 84.0]

P value

(Chi-square test)

Gender

0.40

 Female

74 (36.5%)

77 (30.6%)

151 (33.2%)

 Male

127 (62.6%)

173 (68.7%)

300 (65.9%)

 Other

2 (1.0%)

2 (0.8%)

4 (0.9%)

Country of birth

0.45

 Sweden

181 (89.2%)

230 (91.3%)

411 (90.3%)

 Other

22 (10.8%)

22 (8.7%)

44 (9.7%)

Occupational situation

0.15

 Employed

44 (21.7%)

77 (30.6%)

121 (26.6%)

 Retired

143 (70.4%)

172 (68.3%)

315 (69.2%)

 On sick leave

22 (10.8%)

17 (6.7%)

39 (8.6%)

 Jobseeker

3 (1.5%)

5 (2.0%)

8 (1.8%)

 Student

0 (0%)

2 (0.8%)

2 (0.4%)

 Other

3 (1.5%)

0 (0%)

3 (0.7%)

P value

(Kruskal-Wallis test)

Education

0.11

 No formal schooling

0 (0%)

1 (0.4%)

1 (0.2%)

 Elementary school

34 (16.7%)

29 (11.5%)

63 (13.8%)

 High school

50 (24.6%)

56 (22.2%)

106 (23.3%)

 Vocational training

22 (10.8%)

30 (11.9%)

52 (11.4%)

 University

97 (47.8%)

136 (54.0%)

233 (51.2%)

Health numeracy

< 0.001

 Low

57 (28.1%)

56 (22.2%)

113 (24.8%)

 Medium

82 (40.4%)

66 (26.2%)

148 (32.5%)

 High

64 (31.5%)

130 (51.6%)

194 (42.6%)

Health literacy

0.040

 Low

25 (12.3%)

24 (9.5%)

49 (10.8%)

 Medium

85 (41.9%)

88 (34.9%)

173 (38.0%)

 High

93 (45.8%)

140 (55.6%)

233 (51.2%)

Drug frequency

0.58

 Daily

201 (99.0%)

248 (98.4%)

449 (98.7%)

 1–6 time/week

0 (0%)

0 (0%)

0 (0%)

 1–3 times/month

0 (0%)

1 (0.4%)

1 (0.2%)

 Less than once/month

2 (1.0%)

2 (0.8%)

4 (0.9%)

 No drug

0 (0%)

1 (0.4%)

1 (0.2%)

Disease duration from established PD diagnosis

0.48

 0–6 month

5 (2.5%)

6 (2.4%)

11 (2.4%)

 6–12 month

10 (4.9%)

13 (5.2%)

23 (5.1%)

 1–3 years

32 (15.8%)

43 (17.1%)

75 (16.5%)

 3–5 years

34 (16.7%)

40 (15.9%)

74 (16.3%)

 5–10 years

52 (25.6%)

72 (28.6%)

124 (27.3%)

 10–15 years

35 (17.2%)

44 (17.5%)

79 (17.4%)

 15–20 years

16 (7.9%)

19 (7.5%)

35 (7.7%)

 More than 20 years

19 (9.4%)

15 (6.0%)

34 (7.5%)

P value

(ANOVA^a)

Number of experienced side effects

0.55

 Mean (SD)

3.34 (2.94)

3.18 (2.77)

3.25 (2.85)

 Median [Min, Max]

3.00 [0, 16.0]

2.00 [0, 13.0]

3.00 [0, 16.0]

P value

(Chi-square test)

Any experience of advanced treatment

0.69

 No

158 (77.8%)

200 (79.4%)

358 (78.7%)

 Yes

45 (22.2%)

52 (20.6%)

97 (21.3%)

P value

(Kruskal-Wallis test)

Leftover embryos can be used to treat patients with PD

< 0.001

 Strongly agree

106 (52.2%)

209 (82.9%)

315 (69.2%)

 Agree

63 (31.0%)

34 (13.5%)

97 (21.3%)

 Undecided

26 (12.8%)

4 (1.6%)

30 (6.6%)

 Disagree

1 (0.5%)

0 (0%)

1 (0.2%)

 Strongly disagree

7 (3.4%)

5 (2.0%)

12 (2.6%)

Leftover embryos can be used to treat other diseases

< 0.001

 Strongly agree

86 (42.4%)

188 (74.6%)

274 (60.2%)

 Agree

72 (35.5%)

43 (17.1%)

115 (25.3%)

 Undecided

36 (17.7%)

13 (5.2%)

49 (10.8%)

 Disagree

2 (1.0%)

4 (1.6%)

6 (1.3%)

 Strongly disagree

7 (3.4%)

4 (1.6%)

11 (2.4%)

Leftover embryos can be used to treat diseases even if treatment with iPS cells are available

< 0.001

 Strongly agree

36 (17.7%)

130 (51.6%)

166 (36.5%)

 Agree

47 (23.2%)

50 (19.8%)

97 (21.3%)

 Undecided

64 (31.5%)

37 (14.7%)

101 (22.2%)

 Disagree

34 (16.7%)

21 (8.3%)

55 (12.1%)

 Strongly disagree

22 (10.8%)

14 (5.6%)

36 (7.9%)

Religion

< 0.001

 Not important

58 (28.6%)

143 (56.7%)

201 (44.2%)

 Slightly important

49 (24.1%)

43 (17.1%)

92 (20.2%)

 Moderately important

57 (28.1%)

49 (19.4%)

106 (23.3%)

 Important

25 (12.3%)

14 (5.6%)

39 (8.6%)

 Very important

14 (6.9%)

3 (1.2%)

17 (3.7%)